MBRX — Moleculin Biotech, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1659617 ·
Last close
$0.61
Market Cap
$11.87M
52W High
$3.69
52W Low
$0.16
ADV30
1,667,915
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -7,874,000 | -12,845,000 | 23,363,000 | 10,317,000 | 8,180,000 |
| Dec 2025 | 0 | — | -7,533,000 | 15,552,000 | 22,126,000 | 8,878,000 | 7,120,000 |
| Sep 2025 | 0 | — | -5,906,000 | -25,399,000 | 20,353,000 | 6,703,000 | 47,273,000 |
| Jun 2025 | 0 | — | -5,720,000 | -7,640,000 | 21,593,000 | 7,557,000 | 28,758,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,282,000
Investing CF
$0
Financing CF
$26,897,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-48.59
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-218,849,000
Inventory
—
Receivables
$9,000
ST Investments
—
EBIT TTM
$-27,033,000
Pretax Income TTM
$-30,332,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -25,103,000 | -33,560,000 | 22,126,000 | 7,120,000 | — | -22,735,000 |
| Dec 2024 | 0 | -26,641,000 | -26,048,000 | 16,925,000 | 5,717,000 | — | -23,862,000 |
| Dec 2023 | 0 | -29,631,000 | -29,769,000 | 38,217,000 | 12,144,000 | — | -23,591,000 |
| Dec 2022 | 0 | -30,640,000 | -29,025,000 | 57,422,000 | 5,231,000 | — | -27,639,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-7,557,000
OpCashFlow TTM
$0
Assets (Latest)
$25,235,000
Forward EPS
$-110.50
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GDTC | CytoMed Therapeutics Ltd | $11.83M | $1.00 | — |
| PDSB | PDS Biotechnology Corp | $12.13M | $0.22 | — |
| KPRX | KIORA PHARMACEUTICALS INC | $12.17M | $2.75 | — |
| ASBP | Aspire Biopharma Holdings, Inc. | $10.95M | $7.81 | — |
| QNRX | Quoin Pharmaceuticals, Ltd. | $10.89M | $5.42 | — |
News headlines (Yahoo Finance, 1h cache)
Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why
2026-08-24 16:00 · Yahoo
Moleculin Announces Pricing of $9.3 Million Public Offering
2026-07-31 14:12 · Yahoo
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
2026-07-31 12:10 · Yahoo
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
2026-07-06 12:33 · Yahoo
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance
2026-06-30 18:52 · Yahoo
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
2026-06-30 12:30 · Yahoo
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
2026-06-04 12:31 · Yahoo
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
2026-05-21 21:02 · Yahoo
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
2026-05-15 12:30 · Yahoo
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding
2026-05-13 16:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.